Curis, Inc. (CRIS) Announces Initiation of a Roche-Sponsored Phase 1b/2 Study of Erivedge® (vismodegib) in Relapsed/Refractory AML and High Risk MDS
10/4/2013 9:22:57 AM
LEXINGTON, Mass., Oct. 4, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that Roche initiated a Phase 1b/2 study of Erivedge® (vismodegib) in patients with relapsed/ refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS). Roche and its wholly-owned subsidiary, Genentech, have developed Erivedge under a collaboration agreement with Curis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by